Lotte Biologics Begins Full-Scale Operation of ADC Production Facility

Officials are holding a ribbon-cutting ceremony at the ADC production facility within Lotte Biologics' New York JX Syracuse campus. Photo by Lotte Biologics

Lotte Biologics announced on April 24 that it has signed a contract with an Asia-based biotech company to produce clinical trial candidate materials for ADCs (antibody-drug conjugates).

This contract marks the first signal of the full-scale operation of the ADC production facility at the New York Syracuse Bio Campus, which has been expanded since 2023. The company aims to launch its ADC contract development and manufacturing (CDMO) services, capable of meeting a wide range of customer needs from clinical development to commercial production, and to further strengthen the competitiveness of the Syracuse Bio Campus.

Based on this order, the company plans to seek additional client opportunities and accelerate the expansion of partnerships to provide one-stop ADC services. Through these efforts, Lotte Biologics intends to strengthen its position in the ADC therapeutics market and enhance its status as a global CDMO company.

Lotte Biologics’ ADC production facility, which has received an investment of about $100 million (approximately KRW 142.9 billion), is a cGMP facility offering one-stop services. The facility is equipped with integrated production and purification lines, including a conjugation reactor with a maximum capacity of 1,000 liters. It provides in-house quality control (QC) testing as well as characterization analysis services. In addition, a single-use system has been established, from antibody preprocessing to automated aseptic filling of raw materials, enabling flexible responses to diverse customer requirements.

James Park, CEO of Lotte Biologics, stated, “Starting with this contract, we will reliably supply high-quality ADC pharmaceuticals and solidify our position in the global market not only as a contract manufacturer of antibodies but also of ADCs. We also plan to actively seek collaboration opportunities to further strengthen the competitiveness of our ADC modality business.”

Meanwhile, Lotte Biologics recently held a ribbon-cutting ceremony at its ADC production facility at the New York Syracuse campus. The event was attended by James Park, CEO of Lotte Biologics, Shin Yooyeol, Head of Global Strategy at Lotte Biologics, Michael Housladen, Head of Lotte Biologics USA, as well as approximately 100 Syracuse campus employees.

This content was produced with the assistance of AI translation services.